openPR Logo
Press release

Global Radiopharmaceuticals Market Outlook 2020 Report

05-07-2018 08:39 AM CET | Health & Medicine

Press release from: Kuick Resarch

“Global Radiopharmaceuticals Market Outlook 2020” Report Highlight:

* Global Radiopharmaceutical Market Overview
* Global Radiopharmaceuticals Market Dynamics
* FDA & EMA Guidelines for Radiopharmaceuticals
* Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
* Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
* Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
* Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Radiopharmaceuticals-Market-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Global Radiopharmaceutical Market Overview

1.1 Current Market Scenario

1.2 Diagnostic & Therapeutic Radiopharmaceuticals

1.3 Global Radiopharmaceticals Clinical Pipeline Overview



2. Global Radiopharmaceuticals Market Dynamics



3. Radioisotopes Used in Radiopharmaceuticals



4. EMA Guidelines for Radiopharmaceuticals

4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products

4.2 Toxicological & Pharmacological Tests

4.3 Clinical Documentation

4.4 Radiation Dosimetry

4.5 Labelling & Packaging



5. FDA Guidelines for Radiopharmaceuticals

5.1 Clinical Indication

5.2 General Considerations for Safety Assessments

5.3 Clinical Evaluation of Medical Imaging Agents



6. Canada Guidelines for Radiopharmaceuticals

6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research

6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans

6.3 Stability Testing of Existing Drug Substances and Products

6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)



7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase

7.1 Unknown

7.2 Research

7.3 Preclinical

7.4 Phase-0

7.5 Phase-I

7.6 Phase-I/II

7.7 Phase-II

7.8 Phase-II/III

7.9 Phase-III

7.10 Preregistration



8. Marketed Radiopharmaceuticals Clinical Insight by Indication

8.1 Florbetapir F 18 (Amyvid)

8.2 Iobenguane I-123 (AdreView)

8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)

8.4 Radium-223 Chloride (Alpharadin & Xofigo)

8.5 Tc 99m Tilmanocept (Lymphoseek)

8.6 Florbetaben F18 (NeuraCeq)

8.7 Capromab (ProstaScint)

8.8 Pentetreotide (Oktreotid & 111In)

8.9 Iodine I 131 Derlotuximab Biotin (Cotara)

8.10 Tc 99m Besilesomab (Scintimun)

8.11 Samarium 153 lexidronam (Quadramet)

8.12 Technetium Tc 99m Sulfur Colloid Injection

8.13 Tc 99m Apcitide (AcuTect)

8.14 DW 166HC (Milican)

8.15 Tc 99m Sulesomab (LeukoScan)

8.16 Satumomab (OncoScint CR/OV)

8.17 Pentetreotide (OctreoScan & SomatoTher)

8.18 Tc 99m ior cea1

8.19 Tc 99m Nofetumomab Merpentan (VerLuma)



9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase

9.1 No Development Reported

9.2 Discontinued

9.3 Market Withdrawal

9.4 Suspended





10. Competitive Landscape

10.1 Avid Radiopharmaceuticals

10.2 Actinium Pharmaceuticals

10.3 AREVA Med

10.4 Bayer HealthCare Pharmaceuticals

10.5 Cardinal Health

10.6 Immunomedics

10.7 Lantheus Medical Imaging

10.8 Merck

10.9 Navidea

10.10 Nordion

10.11 Lantheus Medical Imaging

10.12 GE Healthcare

10.13 Ion Beam Applications

10.14 PETNET Solutions (Siemens Healthcare Global)

Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2014-2020

Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2014 & 2020

Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2014 - 2020

Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2014-2020

Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2014 & 2020

Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2014 - 2020

Figure 1-7: Global Radiopharmceutical Pipeline by Phase (%), 2016

Figure 1-8: Global Radiopharmceutical Pipeline by Phase (Numbers), 2016

Figure 1-9: Suspended & Discontinued Radiopharmceutical Pipeline (%), 2016

Figure 1-10: Suspended & Discontinued Radiopharmceutical Pipeline (Number), 2016

Figure 8-1: Lantheus Medical Imaging Product Pipeline



Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug

Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug

Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug

Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug

Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug

Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug

Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug

Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug

Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug

Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug

Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug

Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug

Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug

Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug

Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug

Table 1-16: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug

Table 1-17: Iron-59 Investigation Properties as Radiopharmaceuticals Drug

Table 1-18: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug

Table 1-19: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug

Table 1-20: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug

Table 1-21: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug

Table 1-22: Radium-223 Investigation Properties as Radiopharmaceuticals Drug

Table 1-23: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug

Table 1-24: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug

Table 1-25: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug

Table 1-26: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug

Table 1-27: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug

Table 1-28: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug

Table 1-29: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug

Table 1-30: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug

Table 1-31: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug

Table 1-32: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Radiopharmaceuticals Market Outlook 2020 Report here

News-ID: 1040927 • Views: 433

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Radiopharmaceutical

A Comprehensive Study exploring Radiopharmaceutical Market | Bayer, Triad Isotop …
A latest survey on Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical Market is conducted covering various organizations of the industry from different geographies to come up with 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition is facing along with gap analysis and new opportunity available and may trend in
Global Radiopharmaceutical Market Analysis and Forecast Predictions
The market for Radiopharmaceutical Market growing with the expansion of this Industry Sector Worldwide. Market Research Report Search Engine (MRRSE) has added a new report titled “Radiopharmaceutical Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2024”which offer details about the current trends as well as scope for the near future. This research study also covers information about the production and market share based on different
Radiopharmaceutical Market | Analysis & Key Trends 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. According to the Nuclear Energy Institute, radioisotopes are essential
Radiopharmaceutical Market: Market and Growth Analysis 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. According to the Nuclear Energy Institute, radioisotopes are essential
Growing Demand of Radiopharmaceutical Market in Upcoming Years
The key purpose of the Radiopharmaceutical Market report is to identify, explain, and predict the global market based on various aspects such as Manufacturers, Countries, Type and Application, Forecast, and vertical. The report deliberately scrutinizes every sub-segment concerning the individual growth trends, contribution to the total market, and the future prospects. Radiopharmaceuticals Market are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes.
Radiopharmaceutical Market Development Status and Outlook 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. Read Report Overview for Radiopharmaceutical Market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html According to the